39-desmethoxy-39-methyl derivatives of rapamycin

Details 39-desmethoxy-39-methyl derivatives of rapamycin 39-desmethoxy-39-methyl derivatives of rapamycin

2011-03-01

2011-03-01

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C540S456000

Reexamination Certificate

active

07897608

ABSTRACT:
The present invention relates to novel 39-desmethoxy-39-methylrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 39-desmethoxy-39 -methylrapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal
patent: 5023262 (1991-06-01), Caufield
patent: 5138051 (1992-08-01), Hughes
patent: 5221670 (1993-06-01), Caufield
patent: 5362718 (1994-11-01), Skotnicki
patent: 5378836 (1995-01-01), Kao
patent: 5391730 (1995-02-01), Skotnicki
patent: 5432183 (1995-07-01), Schulte
patent: 5446048 (1995-08-01), Failli
patent: 5563145 (1996-10-01), Failli
patent: 5665772 (1997-09-01), Cottens
patent: 5728710 (1998-03-01), Luengo
patent: 5912253 (1999-06-01), Cottens
patent: 5955457 (1999-09-01), Lee
patent: 6015815 (2000-01-01), Mollison
patent: WO 2003/064383 (2003-08-01), None
patent: WO 2004/007709 (2004-01-01), None
patent: WO 2004/101583 (2004-11-01), None
patent: WO 2006/095185 (2006-09-01), None
Alarcon, C.M., Heitman, J., and Cardenas, M.E. (1999) Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast.Molecular Biology of the Cell10: 2531-2546.
Aparicio, J.F., Molnár, I., Schwecke, T., König, A., Haydock, S.F., Khaw, L.E., Staunton, J., and Leadlay, P.F. (1996) Organization of the biosynthetic gene cluster for rapamycin inStreptomyces hygroscopicus: analysis of the enzymatic domains in the modular polyketide synthase.Gene169: 9-16.
Baker, H., Sidorowicz, A., Sehgal, S.N., and Vézina, C. (1978) Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation.Journal of Antibiotics31: 539-545.
Boulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O'Reilly, T., Stolz, B., Marti, A., Thomas, G., Lane, H.A.,. 2004, Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.Cancer Res. 64(1), 252-61.
Brown, E.J., Albers, M.W., Shin, T.B., Ichikawa, K., Keith, C.T., Lane, W.S., and Schreiber, S.L. (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex.Nature369: 756-758.
Brunn, G.J., Williams, J., Sabers, C., Wiederrecht, G., Lawrence, J.C., and Abraham, R.T. (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.EMBO Journal15: 5256-5267.
Carlson, R.P., Hartman, D.A., Tomchek, L.A., Walter, T.L., Lugay, J.R., Calhoun, W., Sehgal, S.N., Chang, J.Y. (1993). Rapamycin, a potential disease-modifying antiarthritic drug. J. Pharmacol. Exp. Ther. 266(2):1125-38.
Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M. (1999) Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats.Drug Metab Dispos, 27(5), 627-32.
Dengler W.A., Schulte J., Berger D.P., Mertelsmann R. and Fiebig HH. (1995) Development of a propidium iodide fluorescence assay for proliferation and cytotoxicity assay.Anti-Cancer Drugs, 6:522-532.
DiLella, A.G., and Craig, R. J. (1991) Exon organization of the human FKBP-12 gene: correlation with structural and functional protein domains.Biochemistry30: 8512- 8517.
Dudkin, L., Dilling, M.B., Cheshire, P.J., Harwood, F.C., Hollingshead, M., Arbuck, S.G., Travis, R., Sausville, E.A., Houghton, P.J. (2001). Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin. Cancer Res. 7(6):1758-64.
Evans D.A., Gage J.R. and Leighton J.L. (1992) Assymetric synthesis of calyculin A. 3. Assemblage of the calyculin skeleton and the introduction of a new phosphate monoester synthesis.J. Org. Chem., 57:1964-1966.
Fiebig H.H., Dengler W.A. and Roth T. (1999) Human tumor xenografts: Predictivity, characterization, and discovery of new anticancer agents. In: Fiebig HH, Burger AM (eds). Relevance of Tumor Models for Anticancer Drug Development.Contrib. Oncol., 54: 29-50.
Findlay J.A, and Radics, L. (1980)Canadian Journal of Chemistry58:579.
Fishbein, T.M., Florman, S., Gondolesi, G., Schiano, T., LeLeiko, N., Tschernia, A., Kaufman, S. (2002). Intestinal transplantation before and after the introduction of sirolimus.Transplantation. 73(10):1538-42.
Foey, A., Green, P., Foxwell, B., Feldmann, M., Brennan, F. (2002). Cytokine-stimulated T cells induce macrophage IL-10 production dependent on phosphatidylinositol 3-kinase and p70S6K: implications for rheumatoid arthritis.Arthritis Res. 4(1):64-70. Epub 2001 Oct. 10.
Furniss B.S., Hannaford A.J., Smith P.W.G. and Tatchell A.R. (1989)Vogel's textbook of practical organic chemistry, 5th Ed, Pearson, Prentice Hall, Harlow, UK.
Gallant-Haidner HL, Trepanier DJ, Freitag DG, Yatscoff RW. 2000, “Pharmacokinetics and metabolism of sirolimus”.Ther Drug Monit. 22(1), 31-5.
Gregory, C.R., Huie, P., Billingham, M.E. and Morris, R.E. (1993). Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor and cytokine response in injured vessels.Transplantation55(6): 1409-1418.
Gregory MA, Gaisser S, Lill RE, Hong H, Sheridan RM, Wilkinson B, Petkovic H, Weston AJ, Carletti I, Lee HL, Staunton J, Leadlay PF. (2004) “Isolation and characterization of pre-rapamycin, the first macrocyclic intermediate in the biosynthesis of the immunosuppressant rapamycin by S. hygroscopicus”.Angew Chem Int Ed Engl. 43(19), 2551-3.
Gu, J, Ruppen ME, Cai P. (2005), Lipase-Catalyzed Regioselective Esterification of Rapamycin: Synthesis of Temsirolimus (CCI-779). Org. Lett. 7(18): 3945-3948.
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C.J., Zuelke, C., Farkas, S., Anthuber, M., Jauch, K.W., and Geissler, E.K. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.Nature Medicine8: 128-135.
Hardwick, J.S., Kuruvilla, F.G., Tong, J.K., Shamji, A.F., and Schreiber, S.L. (1999) Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins.Proceedings of the National Academy of Sciences of the United States of America96: 14866-14870.
Hentges, K.E., Sirry, B., Gingeras, A.C., Sarbassov, D., Sonenberg, N., Sabatini, D., and Peterson, A.S. (2001) FRAP/mTOR is required for proliferation and patterning during embryonic development in the mouse.Proceedings of the National Academy of Sciences of the United States of America98: 13796-13801.
Jain, S., Bicknell, G.R., Whiting, P.H., Nicholson, M.L. (2001). Rapamycin reduces expression of fibrosis-associated genes in an experimental model of renal ischaemia reperfusion injury.Transplant Proc. 33(1-2):556-8.
Kahan, B.D., and Camardo, J.S. (2001) Rapamycin: Clinical results and future opportunities.Transplantation72:1181-1193.
Kahan, B.D., Chang, J.Y., and Sehgal, S.N. (1991) Preclinical evaluation of a new potent immunosuppressive agent, rapamycin.Transplantation52: 185-191.
Kirby, B., and Griffiths,C.E.M. (2001) Psoriasis: the future.British Journal of Dermatology144:37-43.
Kirchner, G.I., Winkler, M., Mueller L., Vidal, C., Jacobsen, W., Franzke, A., Wagner, S., Blick, S., Manns M.P., and Sewing K.-F.(2000) Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD. British Journal of Clinical Pharmacology 50:449-454.
Kuo, C.J., Chung, J.K., Fiorentino, D.F., Flanagan, W.M., Blenis, J., and Crabtree, G.R. (1992) Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.Natu

Affiliated with

Also associated with

Rating

39-desmethoxy-39-methyl derivatives of rapamycin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 39-desmethoxy-39-methyl derivatives of rapamycin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 39-desmethoxy-39-methyl derivatives of rapamycin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2741684